Search research articles
Contact Us
Filters
Showing results (71-80 of 129) with videos related to
Page
of 13
Sort By:
Oncology
|
April 16, 2016
Characterisation of the Phosphatidylinositol 3-Kinase Pathway in Non-Small Cell Lung Cancer Cells Isolated from Pleural Effusions
Martina Puglisi, Adam Stewart, Parames Thavasu, et al.
Molecular Cancer Therapeutics
|
July 3, 2019
Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in <i>KRAS</i>-Mutant Cancers
Adam Stewart, Elizabeth A Coker, Sebastian Pölsterl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 28, 2017
Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors
Andrew J Wagner, Udai Banerji, Amit Mahipal, et al.
Lung Cancer Management
|
June 4, 2021
HER3 expression and MEK activation in non-small-cell lung carcinoma
Thubeena Manickavasagar, Wei Yuan, Suzanne Carreira, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 26, 2015
First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014
Bristi Basu, Emma Dean, Martina Puglisi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 4, 2012
A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors
Udai Banerji, Leni van Doorn, Dionysis Papadatos-Pastos, et al.
Journal of Immunotherapy and Precision Oncology
|
June 6, 2022
A Wolf in Sheep's Clothing: Systemic Immune Activation Post Immunotherapy
Crescens Tiu, Rajiv Shinde, Abhijit Pal, et al.
British Journal of Cancer
|
April 29, 2023
A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer
Rebecca Kristeleit, Ruth Plummer, Robert Jones, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 13, 2019
Multidisciplinary interventions in a specialist Drug Development Unit to improve family history documentation and onward referral of patients with advanced cancer to cancer genetics services
Cathryn A Moss, Elena Cojocaru, Janet Hanwell, et al.
Oncotarget
|
December 22, 2017
High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy
Raquel Perez-Lopez, Desam Roda, Begona Jimenez, et al.
Page
of 13
Search research articles
Search
Showing results (71-80 of 129) with videos related to
Sort By:
Page
of 13
Oncology
|
April 16, 2016
Characterisation of the Phosphatidylinositol 3-Kinase Pathway in Non-Small Cell Lung Cancer Cells Isolated from Pleural Effusions
Martina Puglisi, Adam Stewart, Parames Thavasu, et al.
Molecular Cancer Therapeutics
|
July 3, 2019
Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in <i>KRAS</i>-Mutant Cancers
Adam Stewart, Elizabeth A Coker, Sebastian Pölsterl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 28, 2017
Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors
Andrew J Wagner, Udai Banerji, Amit Mahipal, et al.
Lung Cancer Management
|
June 4, 2021
HER3 expression and MEK activation in non-small-cell lung carcinoma
Thubeena Manickavasagar, Wei Yuan, Suzanne Carreira, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 26, 2015
First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014
Bristi Basu, Emma Dean, Martina Puglisi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 4, 2012
A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors
Udai Banerji, Leni van Doorn, Dionysis Papadatos-Pastos, et al.
Journal of Immunotherapy and Precision Oncology
|
June 6, 2022
A Wolf in Sheep's Clothing: Systemic Immune Activation Post Immunotherapy
Crescens Tiu, Rajiv Shinde, Abhijit Pal, et al.
British Journal of Cancer
|
April 29, 2023
A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer
Rebecca Kristeleit, Ruth Plummer, Robert Jones, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 13, 2019
Multidisciplinary interventions in a specialist Drug Development Unit to improve family history documentation and onward referral of patients with advanced cancer to cancer genetics services
Cathryn A Moss, Elena Cojocaru, Janet Hanwell, et al.
Oncotarget
|
December 22, 2017
High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy
Raquel Perez-Lopez, Desam Roda, Begona Jimenez, et al.
Page
of 13